1 / 18

V pliv presejalnih programov na incidenco in preživetje

V pliv presejalnih programov na incidenco in preživetje. Branko Zakotnik. www.dpor.si. Predstavljeno na EPH Konferenci v Ljubljan i , 30 .1 1 .2018. Vsebina. Uvod ZORA SVIT DORA Zaključek. Strateški cilji DPOR: znižati incidenco povečati preživetje

eschroyer
Download Presentation

V pliv presejalnih programov na incidenco in preživetje

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Vpliv presejalnih programov na incidenco in preživetje Branko Zakotnik www.dpor.si Predstavljeno na EPH Konferenci v Ljubljani, 30.11.2018 Seja strokovnega sveta DPOR 17.4.2019, Ministrstvo za zdravje

  2. Vsebina • Uvod • ZORA • SVIT • DORA • Zaključek

  3. Strateški cilji DPOR: • znižati incidenco • povečati preživetje • izboljšati kvaliteto življenja s celostno rehabilitacijo in paliativno oskrbo

  4. povečati preživetje znižati incidenco - 5 year male male female female

  5. ZORA

  6. Incidence 2003: 211 2017: 82 129 (61%)! CERVICAL CANCER Conventional cytology, three-year screening intervals, 20–64 age group, Participation rate >70%

  7. 92.1 63.7 HR=0,18; 95% CI 0,11- 0,28 p<0,0001

  8. Cervical cancer - Stage (FIGO) distribution: ZORA vs notZORA Chi-square p<0,00001

  9. SVIT

  10. Incidence 2010: 1729 2015: 1357 372 (21%)! COLORECTAL CANCER SVIT Immunochemical faecal occult blood test and follow up colonoscopy if positive. 50-74 age group Interval: 2 years Participation rate: 60%

  11. 88.4 57.1 HR=0,26; 95% CI 0,23-0,29; p<0,0001 SVIT

  12. Colorectal cancer - Stage (TNM) distribution: SVIT vs notSVIT Chi-square p<0,00001

  13. DORA

  14. Incidence 2008: 1171 2015: 1324 153 (13%)! BREAST CANCER Mamografy every 2 years, 50-69 years age group Participation rate: 73%

  15. 100 89 HR=0,25; 95% CI 0,17-0,37; p<0,0001

  16. Breast cancer - Stage (TNM) distribution: DORA vs notDORA Chi-square p<0,00001

  17. Prostate cancer Incidence 2015:1541! PSA *unknown

  18. ZAKLJUČEK • Kvalitetni presejalnimi programi (ZORA, SVIT, DORA) pomembno prispevajo k obvladovanju raka v državi • Le s prispevkom vsakega posameznika na področju primarne in sekundarne preventive bomo sposobni obvladovati epidemijo 21. stoletja (kadri, stroški) www.dpor.si

More Related